



New Report: Unlocking HCV Care In Key Settings Convening Summary

The four key settings discussed have particular value and significance for their potential in engaging people with high burdens of HCV and high barriers to health care access.

December 8, 2023 By [NVHR](#)

In September of this year, NASTAD and NVHR convened a two-day virtual summit entitled [Unlocking HCV Care in Key Settings](#) with an estimated 600 participants in attendance.

The four key settings discussed—programs that provide medications for opioid use disorder, state correctional facilities, federally qualified health centers, and syringe services programs—have particular value and significance for their potential in engaging people with high burdens of HCV and high barriers to health care access.

Throughout the convening, panelists and discussants spotlighted strategies to integrate HCV testing and treatment in these settings, providing detailed examples of program design, staffing considerations, financing and reimbursement options, and enabling factors for successful implementation.

[A summary report for Unlocking HCV Care in Key Settings](#) is now available, and comes on the heels of two other significant analyses: a viral hepatitis [surveillance status report](#) released by HepVu and NASTAD and a [policy brief](#) from the Duke-Margolis Center for Health Policy outlining an

implementation strategy including multiple recommendations focused on health care financing and delivery. These publications provide vital blueprints for advocacy and action, and collectively they put forth a striking vision of HCV elimination.

Slides and recordings for each key setting:

- [Medications for opioid use disorder \(MOUD\) programs](#)
- [State correctional facilities](#)
- [Federally qualified health centers \(FQHCs\)](#)
- [Syringe services programs \(SSPs\)](#)

NVHR is grateful to our NASTAD partners, as well as the moderators, panelists, discussants, and attendees of the virtual summit and the planning team and reviewers. We welcome feedback and suggestions on the summary report and look forward to working with all of you in 2024 on making the promise of HCV elimination a reality.

For more information on our collaboration with NASTAD, visit [HepNET](#).